Reported 1 day ago
Novo Nordisk's CEO Lars Fruergaard Jorgensen is stepping down following concerns that the company is losing its competitive edge in the obesity drug market. Analysts express surprise and highlight that the change comes during a challenging time for Novo, with significant stock declines and increased pressure from rivals like Eli Lilly. The departure marks a notable shift for the company, which has not seen a CEO change this way since 1960, prompting discussions about its future strategy and competitive positioning.
Source: YAHOO